|
|
Klappacher Straße 126
Darmstadt, 64285 Germany
phone:0049 (0)6151 951 58 12
fax:0049 (0)6151 951 58 13
|
|
| Symbol |
T5O |
| Exchange |
FRA |
| Founded |
0 |
| Employees |
|
|
|
| www.cytotools.de
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Novel therapies in Atherosclerosis and other vascular diseases. |
|
| Management |
| Mark Andre Freyberg, Chief Executive Officer |
| |
|
|
|
|
|
|
|
| Keywords |
| biotechnology, vascular, atherosclerosis, blood, vessel, disease, endothelial, tissue, damage, elucidating, cell, organ, culture |
|
|
|
| Description |
|
CytoTools is focused on the development of novel therapies in vascular diseases. Atherosclerosis is the most common and important form of blood vessel disease and causes more than 50% of all deaths in the US and Europe. The development and approval of novel compounds targeting the cause of this terrible disease is its goal. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
